Anna M. Puzio-Kuter

Anna M. Puzio-Kuter

Auto-generated profile, based on publicly available information

Anna M. Puzio-Kuter

PMV Pharmaceuticals, Inc. 1 , Princeton, New Jersey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Cancer Discovery
Verified
Journal Article
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
Restoration of the tumor suppressor function of tumor-associated p53 mutants, including the Y220C substitution, has posed a significant challenge for therapeutic discovery. In this study, we describe rezatapopt (PC14586), part of a series of compounds designed to reactivate the p53 Y220C mutant. These compounds restore p53 tumor suppressor function by correcting its conformation and enabling it to bind DNA and activate downstream target genes, thus inducing antiproliferative changes in tumor cells. Our findings are supported by biochemical and structural analysis, in vitro and in vivo transcriptomics, and functional data, revealing the recovery of multiple aspects of the wild-type p53 program. These compounds demonstrate potent antitumor activity in preclinical models as single agents and in combination with immunotherapy. Currently, rezatapopt is being evaluated in a registrational phase II clinical trial for patients with advanced solid tumors harboring the TP53 Y220C mutation. Significance: Rezatapopt is a clinical-stage compound that offers a promising treatment option for TP53-mutant cancers. This study details the characterization of rezatapopt and its related compounds, which can reinstate the tumor suppressor activity of the p53 Y220C mutant. These results emphasize the potential for targeting p53 mutations in cancer therapy.

20 November 2025 in Blood
Verified
Journal Article
Closed access
BCBing Z. Carter
Bing Z. Carter
PMPo Yee Mak
Po Yee Mak
EAEdward Ayoub
Edward Ayoub
XWXiaogang Wu
Xiaogang Wu
BKBaozhen Ke
Baozhen Ke
MAMichael Andreeff
Michael Andreeff
TP53-Y220C is a recurrent hot spot mutation in cancers and leukemias. It is observed predominantly in acute myeloid leukemia (AML)/myelodysplastic syndromes among hematological malignancies and is associated with poor outcome. The mutation creates a structural pocket in the p53 protein. PC14586 (rezatapopt) is a small molecule designed to bind to this pocket and thus restore a p53 wild-type (p53-WT) conformation. We demonstrate that PC14586 converts p53-Y220C into a p53-WT conformation and activates p53 transcriptional targets but surprisingly induces limited/no apoptosis in TP53-Y220C AML. Mechanistically, MDM2 induced by PC14586-activated conformational p53-WT and the nuclear exporter exportin 1 (XPO1) reduce the transcriptional activities of p53, which are fully restored by inhibition of MDM2 and/or XPO1. Importantly, p53-WT protein can bind to B-cell lymphoma 2 (BCL-2), competing with BCL-2-associated X protein (BAX) in the BH3 binding pocket of BCL-2, and also binds to BCL-xL and myeloid cell leukemia 1 (MCL-1). However, such binding by PC14586-activated conformational p53-WT is not detected. Pharmacological inhibition of the BCL-2/BAX interaction with venetoclax fully compensates for this deficiency, induces massive cell death in AML cells and stem/progenitor cells in vitro, and prolongs survival of TP53-Y220C AML xenografts in vivo. Collectively, we identified transcription-dependent and -independent mechanisms that limit the apoptogenic activities of reactivated conformational p53-WT and suggest approaches to optimize apoptosis induction in TP53-mutant leukemia. A clinical trial of PC14586 in TP53-Y220C AML/myelodysplastic syndromes has recently been initiated. This trial was registered at www.ClinicalTrials.gov as #NCT06616636.

3 June 2025
Verified
Other
Open access
PDF file
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
Supplementary Figure S1. Functional Characterization of p53-Y220C Reactivator Compounds. Supplementary Figure S2. Reactivator Compounds are Active Only in p53-Y220C Cell Lines. Supplementary Figure S3. Selective Restoration of Wild-Type (WT) p53 Transcriptional Responses by PC14586 in Cells. Supplementary Figure S4. In Vivo Administration of PC14586 Leads to Tumor Growth Inhibition of Activation of Downstream Biomarkers. Supplementary Figure S5. PC14586 Restored Multiple Facets of Dynamic Wild-Type (WT) p53 Transcriptional Responses in Vivo. Supplementary Figure S6. PC14586 Administration in Vivo Led to Regulation of Genes Specific for Immune and Inflammatory Responses. Supplementary Figure S7. Clinical Timelines of Two Patients with Advanced Solid Tumors Harboring a TP53 Y220C Mutation Receiving Rezatapopt.

3 June 2025
Verified
Other
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
Selective restoration of WT p53 transcriptional responses by PC14586 in cells. A, Quantification of CDKN1A (p21) and MDM2 mRNA by qRT-PCR in p53-Y220C, other p53 hotspot mutants, p53 WT, and p53 KO cell lysates following 5 hours of treatment with rezatapopt (PC14586). Data for the top four cell lines were representative results of three biological repeats, data for other cell lines were from two biological repeats, and graphs were plotted as mean ± SD. A.U., arbitrary unit. B, Scatter plots showing expression levels of genes involved in the p53 signaling pathway in cells following treatment with rezatapopt (PC14586). RNA samples extracted from p53-Y220C–expressing cells (NUGC-3), p53 KO cells (NUGC-3 KO) treated with rezatapopt (PC14586; 5 µmol/L, 16 hours), and NUGC-3 KO_p53i cells induced with doxycycline (50 ng/mL, 12.5 hours) were profiled by the Qiagen RT2 p53 pathway qRT-PCR panel. Scales are in log10 (relative expression to housekeeping genes; n = 3). C, Scatter plots of log2 (transcripts per million + 0.01) and volcano plots of −log10 (FDR) versus log2 (fold change) from RNA-seq analysis of expressed genes from p53-Y220C and p53 KO cell lines following DMSO and rezatapopt (PC14586; 5 µmol/L) treatment (16 hours). Genes enriched in gene sets of Fischer direct p53 targets (upregulated), Fischer DREAM Targets (downregulated), DEGs excluding the above-enriched genes (upregulated and downregulated), and non-DEGs were sequentially overlaid as indicated. D, Top enriched gene sets from GSEA of the Molecular Signatures Database C2 collection curated gene sets in the indicated RNA-seq data (NUGC-3 treated with 5 µmol/L PC14586 versus DMSO for 16 hours) from DEGs (Walden stat preranked). The number of overlapping genes from the upregulated DEGs enriched in both the Fischer direct p53 targets gene set, and each listed gene set was divided by the total number of genes in each listed gene set and then multiplied by 100 to obtain the overlap with Fischer_Direct_p53_Targets (%). Overlap with Fischer DREAM targets (%) was calculated in a similar manner, except using the downregulated DEGs. To calculate enrichment (%), the number of genes from the DEGs with the indicated direction of regulation enriched in each gene set was divided by the total number of genes in each listed gene set and multiplied by 100. Normalized enrichment scores (NES) and percentages (%) were plotted on the upper and lower x-axes. All gene sets shown had enrichment of FDR q value (q) <0.001. Note that the names of gene sets were shortened. See Supplementary File S11 for details. E, Examples of the GSEA enrichment plots from D. F, Schematic representation of p53 in the transcriptional repression of cell-cycle genes via retinoblastoma-E2F and DREAM complexes. CDK, cyclin-dependent kinase; RBL, retinoblastoma-like proteins p107 (RBL1) and p130 (RBL2).

3 June 2025
Verified
Other
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
P53 pathway profiling analysis in NUGC-3 KO_p53i cells induced with doxycycline (50 ng/ml) vs. PBS control (12.5 h).

3 June 2025
Verified
Other
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
GSEA analysis using MSigDB Hallmark gene sets collection (H) for all detected genes demonstrated the regulation of genes for immune and inflammatory response in vivo in NUGC-3 xenograft tumors following 8 h of treatment with 100 mg/kg PC14586.